The European Union can approve the vaccine against Johnson & Johnson’s COVID-19 in March and start distributing it in the same way

The European Medicines Agency can approve Johnson & Johnson’s antiquities vaccine in March and the UE could empress to distribute the finals of the same month, declared the domino of the French Minister of Industry, Agnès Pannier-Runacher.

The European Union (EU) approves the vaccine “as of March, the European Medicines Agency is reviewing all information provided by Johnson & Johnson in order to help[la] on the market ”, Pannier-Ruancher stated in the France 3 television program.

The first dose of deberían “read the March finals or the principles of April”, aggregate, although these places are still being discussed with the laboratory. “It’s a good news because this vaccine only needs a dose, in which case it is possible to require reflux injections, but we do not know,” he said.

Following a graphic unveiled by the European Juvenile Commission, the EU should have received around 600 million doses for the June finals, if all the entries are made according to the forecast. The UE sees the goal of evacuating 70% of the adult population, that is, 225 million people, for the sake of the boreal verona.

The United States has authorized Johnson & Johnson’s vacancy for 18 years. El desarrollo can be refrigerated at room temperature, which “offers logistical and practical sales”.

The keys to Johnson & Johnson’s vacancy

1-Unit dose and refrigerator

Denominated Ad26.COV2.S, see administra en una sola dosis muscle. In each case, you can apply up to two years with a condensing system at -20 ° C and up to three months refrigerated in freezers at 2-8 ° C.

This is a distinctive feature of the Pfizer and Modern dosage requirements. In addition, by the hecho of which can normalize normal temperatures of never in a place of companions, facilitates the logistics of distribution and conservation, and counterposition to its competitors who require ultra freezers.

2-Efficacy

The inoculum has a 66% reduction efficiency in COVID-19 prevention of moderate to severe. The regulatory agency confirms that the injection of J&J -which should help to accelerate the vacancies to require only a dose in place of dose- is safe to use.

At the beginning of this month, Johnson & Johnson assured that clinical trial data were obtained at the global level participates in 44,000 people, indicates that his vacancy against COVID-19 has one general effectiveness in the immunization rate against the 66% rate; a 72% in the tests carried out in the United States; 61% in Latin America and 64% in South Africa, where one more resistant variant has been extended.

If you want these numbers to be as high as those of your competitors, all COVID-19 vacancies from around the world have tried different shapes, which makes the comparisons impossible. Although it is not surprising that a dose results in a few more debilitating issues, the political leaders decide if it is an acceptable compensation to ensure that more people are evacuated more quickly.

Globe 3-Investigations

The clinical trials of this new vaccine demonstrated that 86% of cases are serious in the United States and 82% in Latin America., which in practice means that it is extremely effective in preventing hospitalizations and deaths from the SARS-CoV-2 virus. The hecho of this vacancy was thought to be administered in a sole injection, in contrast to the Pfizer and Modern, which required dose, the convection in one of the most desperate, that accelerated the vacancy campaign.

A decade ago, investigators from Beth Israel Deaconess Medical Center in Boston, United States, developed a method to evacuate a virus called Adenovirus 26, or Ad26 to abbreviate. The Johnson & Johnson company develops vacancies for Ebola and other diseases with Ad26 and now accounted for the flaming approach -limitada by the global context of sanitary emergence- for its inoculant against the coronavirus. In March, 456 million dollars were collected from the United States government to support its advance in production. Despite the fact that vaccine proportional protection in experiments with monos, Johnson & Johnson commenced the Phase I / II trials in July. Different from other vacancies leads in clinical trials, the company uses one dose, no dose.

Johnson & Johnson launched a Phase III follow-up in September, which will be released on October 12 to investigate an adversarial reaction. The juice is reconstituted once diced. Although Johnson & Johnson initially proposed to recruit 60,000 volunteers, it limited the juvenile to 45,000 in December and announced that the cases would be increased.

On January 29, Johnson & Johnson announced that the team had demonstrated that the vaccine was safe and effective. On February 24, the FDA published its proposed analysis, concluding that the vaccine had an effect of 72 per cent in the United States, 64 per cent in South Africa and 61 per cent in Latin America. On the following day, Bahrain converts to the first country to authorize the vaccine for emergency use.

South Africa abandons its plans to use the AstraZeneca vaccine for its health workers after a small test in a demonstration that was effective against variant B.1.351, which has dominant dominance in all countries. Comenzaron uses Johnson & Johnson and su lugar.

MORE ABOUT THIS THEME: